In December 2019, a distinct clinical presentation of pneumonia was first described in China as being caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By January 2020, the virus spread Reference Clark, Sanchez-de-Toledo and Bautista-Rodriguez1–Reference Kobayashi, Dionne and Ferraro5 with adults developing systemic hyperinflammation and myocardial injury. Reference de Diniz, Cardoso and Sawamura6 children made up 2–6% of cases initially but were mostly asymptomatic. Some had mild respiratory symptoms, and the few with comorbidities required hospitalisation or intensive care. Reference Capone, Subramony and Sweberg7
In April 2020, the first reports of paediatric systemic inflammatory syndrome related to severe SARS-CoV-2 emerged from the United Kingdom at the peak of the pandemic in Europe. Reference Capone, Subramony and Sweberg7–Reference Feldstein, Rose and Horwitz13 The syndrome consisted of hypotension, multiorgan involvement, and systemic inflammation. The following month, reports from the rest of Europe and North America validated the severity of this unfolding hyperinflammatory condition by comparing it to Kawasaki disease, toxic shock syndrome, and macrophage activation syndrome. Reference Kavurt, Bağrul and Gül2,Reference Kıymet, Böncüoğlu and Şahinkaya3,Reference Kobayashi, Dionne and Ferraro5,Reference Jhaveri, Ahluwalia and Kaushik14–Reference Minocha, Phoon, Verma and Singh17 The Centers for Disease Control and Prevention published a case definition for disease surveillance and called the condition multisystem inflammatory syndrome in children. Reference Feldstein, Tenforde and Friedman18 The definition is based on age <21 years old, the presence of fever ≥38.0°C for ≥24 hours, increased inflammatory markers (such as ferritin, C-reactive protein, fibrinogen, procalcitonin), the involvement of two or more organ systems, COVID-19 infection or exposure within prior 4 weeks, and exclusion of other diagnoses. Reference Racko, Smane, Klavina, Pucuka, Roge and Pavare19,Reference Shabab, Dubisky, Singh, Crippen, Abulaban and Aldrich20
Initial reports confirm the development of myocarditis and/or left ventricular systolic dysfunction. Reference Sözeri, Çağlayan and Atasayan21 This includes coronary artery dilation and aneurysms, Reference Ramcharan, Nolan and Lai22,Reference Alsaied, Tremoulet and Burns23 cardiac conduction abnormalities, and up to a 12% rate of dysrhythmias. Reference Alsaied, Tremoulet and Burns23,Reference Regan, O’Byrne and Stewart24 In severe cases of multisystem inflammatory syndrome in children, patients were presenting in shock requiring fluid resuscitation, inotropic support, mechanical ventilation, and, in most severe cases, extracorporeal membrane oxygenation. Reference Alsaied, Tremoulet and Burns23 There have been numerous heterogenous small case series reporting cardiac complications in multisystem inflammatory syndrome in children with the largest samples coming from Belay et al Reference Belay, Abrams and Oster25 (n = 1563), Bowen et al Reference Bowen, Miller and Zambrano26 (n = 2818), and Miller et al Reference Miller, Zambrano and Yousaf27 (n = 4470). However, there has never been an attempt to combine these studies to establish the prevalence of these cardiac symptoms.
By determining the accurate prevalence, providers will better anticipate the outcome of their patients and approach discussions about the appropriate frequency of monitoring outside the acute period. Our objective was to perform a systematic review and meta-analysis of the multisystem inflammatory syndrome in children patients, focusing specifically on the associated cardiac sequelae and mortality.
Methods
Design
This is a systematic review and meta-analysis consisting of studies to determine the prevalence of different cardiac complications secondary to multisystem inflammatory syndrome in children. In summary, we included prospective and retrospective cohorts at single-centre and multi-centre facilities both in the United States and internationally. We conducted electronic searches of Ovid MEDLINE, Ovid EMBASE, and World Health Organization COVID-19 Literature Database from the inception of the SARS-CoV-2 pandemic to 1 January, 2022. Two authors independently screened the abstracts and full texts, extracted the data, and resolved disagreements by discussion with a third reviewer.
Types of studies
We included studies enrolling children and adolescents from ages 0 to 21 years of age with multisystem inflammatory syndrome in children-associated SARS-CoV-2 infection that discussed the most frequently associated cardiac manifestations. The search included information both from single and multi-centre institutions. It encompassed a diversified blend of retrospective and prospective data that were observational and contained cross-sectional, cohort, and case studies with greater than ten patients. Articles in languages other than English were considered eligible and translated via Google Translation.
We limited our review to studies assessing myocardial function via echocardiogram to define left ventricular systolic dysfunction as an ejection fraction ≤60%. Studies that discussed other echocardiographic measurements such as fractional shortening and tricuspid annular plane systolic excursion by M-mode, early and late mitral inflow peak velocities by spectral Doppler, and early diastolic septal and lateral mitral annular peak velocities were included but not the primary parameter evaluated. Simpson’s biplane method was the most consistently reported measurement among previous reviews and implemented for this work. We used studies that classified coronary artery abnormalities as described by the Boston Children’s Hospital z-score system. Normal was <2, dilation ≥2 to <2.5, and aneurysm ≥2.5. We also chose to report electrocardiographic dysrhythmias and abnormalities as a combined outcome since many articles did not report specific findings. Studies that defined myocarditis according to clinical presentation (shock, hypotension, chest pain, palpitations, or hypoxia) and diagnostic criteria were selected. Papers describing diagnostic criteria dependent upon electrocardiographic abnormalities (ST/T wave changes, ventricular dysrhythmias, and intraventricular conduction delay), elevated troponin or brain natriuretic peptide, functional/structural abnormalities on echocardiogram or cardiac magnetic resonance, and tissue characterisation by cardiac magnetic resonance per the Lake Louise criteria were incorporated.
We excluded clinical guidelines, systematic reviews, meta-analyses, editorials, and commentaries. Studies looking at multisystem inflammatory syndrome related to the adult population were also excluded, as well as articles discussing solely disease pathogenesis, molecular biology, immunology, other serotypes of coronavirus, or viral agents. Reports of multisystem inflammatory syndrome in children along with discussions of an emergency room course focus on radiological findings (x-rays, CT, or ultrasound), medication trials, case reports with <10 patients, or letters to the editor that were solely perspective or commentary pieces not describing specific cases of multisystem inflammatory syndrome in children were also excluded.
Types of participants
We included studies that enrolled children and adolescents (aged 0–21 years), diagnosed with multisystem inflammatory syndrome in children, and which reported myocardial dysfunction, conduction abnormalities, shock, and/or coronary disease. The summary table (Supplementary Table S1) gives an overview of the country of origin of the study, single or multi-centre, number of patients, number needing ICU, predominant comorbidity, and number of deceased patients.
Types of outcome measures
Our primary outcome was determining the prevalence of subjects requiring vasopressor support, left ventricular systolic dysfunction, electrocardiographic changes including dysrhythmias, coronary abnormalities (dilations and/or aneurysms), ECMO, and mortality. Our secondary outcome was identifying the prevalence of myocarditis by stratifying via method of diagnosis (Supplementary Table S3). Some studies incorporated cardiac MRI and identified myocarditis by assessing myocardial inflammation using the Lake Louise Criteria. In instances where MRI was not available, the remaining authors diagnosed myocarditis per criteria described within their manuscript (Denoted as Predetermined Criteria and Definition of Myocarditis According to Study in Supplementary Table S3). For the studies that did not characterise this measure, we defined myocarditis as left ventricular systolic dysfunction [ejection fraction < 55%], troponin, and/or brain natriuretic protein above the threshold of normal per the study, and any symptomatology [hypotension, shock, inotrope requirement, or oxygen requirements] (Denoted as Strict Criteria in Supplementary Table S3). The specific threshold per study for the definition of left ventricular systolic dysfunction and normal values used for troponin/brain natriuretic peptide/pro-brain natriuretic peptide are listed in Supplementary Table S3. Among all studies, dilation of a coronary artery was defined as a Z-score ≥2 to <2.5 and an aneurysm of coronary vessel as ≥2.5 per the Boston Children’s Hospital z-score system. Reference Sirico, Basso and Reffo28
Search methods for identification of studies
For this systematic review, we performed a search in MEDLINE (PubMed), EMBASE (Ovid), and the WHO Global Research on Coronavirus Disease (COVID-19) Literature Database (https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/) from the inception of the SARS-CoV-2 pandemic to 1 January, 2022 (Supplemental Online Data). The search included keywords and controlled vocabulary for coronavirus/COVID-19 and for the heart and select cardiac complications (Supplemental File 1). We imported the results to Covidence (version 1238, Melbourne, Australia), which detected duplicates.
Selection of studies
Two out of three reviewers (CC, MK, CFF) independently examined each potential study (as randomly assigned by Covidence) and decided on their inclusion in the review (Fig 1), based on its methods and outcomes. We performed this process without blinding of study authors, institutions, journals of publication, or results. We resolved disagreements by reaching consensus among review authors.
Data extraction and management
For each study included in the systematic review, two authors (CC & MK) independently extracted data. We resolved disagreements by discussion and another author (OK) providing the tie-breaking vote. We contacted all authors for their assistance in obtaining missing data pertinent to our analysis of primary outcomes. We also sought the authors’ support with calculating the number of myocarditis cases in their study based on our strict clinical criteria.
Assessment of risk of bias in included studies
We evaluated the validity and design characteristics of each study looking for major potential biases such as study participation, study attrition, prognostic factor measurement, outcome measurement, study confounders, and statistical analysis. Reference Hayden, van der Windt, Cartwright, Côté and Bombardier29 Two authors reviewed and ranked each study’s quality factor separately and defined studies as having low risk of bias only if they adequately fulfilled all the criteria.
Assessment of prevalence
We reported the prevalence and its 95% confidence interval as the number of patients with the outcomes of interest (vasopressor support, left ventricular systolic dysfunction, myocarditis, electrocardiographic dysrhythmias, coronary abnormalities including dilations and/or aneurysms, extracorporeal membrane oxygenation, and mortality over the total number of enrolled patients). To account for small proportions and interval confidences close to 0, we pooled the individual proportions using arcsine transformation. Reference Barendregt, Doi, Lee, Norman and Vos30
Assuming each study estimated a study-specific true effect, we used random-effect models to pool odds ratios. Such models assume no a priori knowledge about the association between the real, or apparent, prevalence; the differences between the studies are considered to be random. These models account for heterogeneity, with the centre of this distribution describing the average of the effects, and its width describing the degree of heterogeneity. We used the DerSimonian-Laird random-effect method in the presence of significant heterogeneity. Reference DerSimonian and Kacker31
Assessment of heterogeneity
We explored heterogeneity using the I2 statistic. An I2 statistic higher than 50% represented substantial heterogeneity. 32
Sensitivity analysis
To further explore the effect of risk of bias, we conducted a sensitivity analysis, removing studies with a high risk of bias.
Statistical Analyses
Meta-analysis was undertaken using a random-effects model, conducted using the Open-Meta [Analyst] program (School of Public Health, Brown University, Providence, RI, USA). Forest plots of prevalence were calculated with 95% CI.
Results
Studies
We identified a total of 2858 references, of which 657 were duplicates and therefore removed from review, leaving a total of 2201 studies that were screened. A total of 1984 studies were not relevant to this review, leaving 217 full-text articles. From these, 94 met eligibility criteria (Fig 1). Of the articles, 71 (75.5%) were solely retrospective studies Reference Clark, Sanchez-de-Toledo and Bautista-Rodriguez1,Reference Kıymet, Böncüoğlu and Şahinkaya3,Reference Kobayashi, Dionne and Ferraro5–Reference Abdel-Haq, Asmar and Deza Leon12,Reference Gün, Kendirli and Botan15,Reference Minocha, Phoon, Verma and Singh17,Reference Racko, Smane, Klavina, Pucuka, Roge and Pavare19,Reference Shabab, Dubisky, Singh, Crippen, Abulaban and Aldrich20,Reference Ramcharan, Nolan and Lai22,Reference Regan, O’Byrne and Stewart24–Reference Sirico, Basso and Reffo28,Reference Belhadjer, Méot and Bajolle33–Reference Whittaker, Bamford and Kenny81 , 7 (7.4%) studies had a mix Reference Feldstein, Rose and Horwitz13,Reference Feldstein, Tenforde and Friedman18,Reference Acevedo, Piñeres-Olave and Niño-Serna82–Reference Torres, Izquierdo and Acuña86 of retrospective and prospective components, and 17 (17%) were prospective Reference Kavurt, Bağrul and Gül2,Reference García-Salido and de Carlos Vicente4,Reference Lima-Setta, Magalhães-Barbosa and Rodrigues-Santos16,Reference Sözeri, Çağlayan and Atasayan21,Reference Ben-Shimol, Livni and Megged87–Reference Yagnam, Izquierdo, Villena, Gonzalez and Drago98 studies. Fifty-six studies were from a single centre, and thirty-eight were from multiple centres. A summary of the included studies is presented in Supplementary Table 1.
Prevalence of overall results
Among the 86 studies that report vasopressor use, the prevalence is 48.2% (95% CI 45.1%; 51.3%), n = 14,593, I2 = 89.70%, Supplemental Figure S1(A). Of the 88 studies that report, left ventricular systolic dysfunction, the prevalence is 37.2% (95% CI 34.1%; 40.3%), n = 14,594, I2 = 90.2%, Supplemental Figure S2(A). Among the 80 studies that report myocarditis, the prevalence is 34.1% (95% CI 30.5%; 37.8%), n = 13,293, I2 = 92.6%, Supplemental Figure S3(A). Of the 59 studies that report electrocardiographic abnormalities, the prevalence is 23.1% (95% CI 18.8%; 27.6%), n = 11,470, I2 = 95.5%, Supplemental Figure S4 (A). Among the 90 studies that report coronary abnormalities, the prevalence is 18% (95% CI 16%; 20%), n = 14,707, I2 = 83.4%, Supplemental Figure S5(A). For the 77 studies that report extracorporeal membrane oxygenation use, the prevalence is 2.2% (95% CI 1.7%, 2.8%), n = 12,778, I2 = 53.8%, Supplemental Figure S6(A). Among the 90 studies that report mortality, the prevalence is 2.2% (95% CI 1.7%; 2.8%), n = 14,620, I2 = 43.8%, Supplementary Figure S7(A).
Assessment of the risks of bias
The overall risk of bias was estimated to be low. We assessed that the risk of bias was low in 60 studies (63.8%), moderate in 23 studies (24.4%), and high in 11 studies (11.76%). The full assessment is shown in Supplementary Table S2.
Sensitivity analysis based on the quality of evidence
For this sensitivity analysis, we removed the studies with a high risk of bias and included those with low and moderate risk of bias. Of the 77 studies that report vasopressor use, the prevalence is 49.1% (95% CI 45.8%; 52.3%), n = 14,280, I2 = 90.3%, Supplemental Figure S1(B). Among the 79 studies remaining that report left ventricular systolic dysfunction, the prevalence is 37.3% (95% CI 34.1%; 40.6%) n = 14,318, I2 = 90.8%, Supplemental Figure S2(B). Of the 74 studies that report myocarditis, the prevalence is 34.1% (95% CI 30.5%; 37.9%), n = 13,109, I2 = 93%, Supplemental Figure S3(B). Among the 56 studies that report electrocardiographic abnormalities, the prevalence is 21.4% (95% CI 17.3%; 25.8%), n = 11,363, I2 = 95.3%, Supplemental Figure S4(B). Of the 81 studies that report coronary abnormalities, the prevalence is 18.2% (95% CI 16.2%; 20.4%), n = 14,422, I2 = 84.7%, Supplemental Figure S5(B). Among the 70 studies that report extracorporeal membrane oxygenation utility, the prevalence is 2.3% (95% CI 1.7%; 2.9%), n = 12,514, I2 = 57.7%, Supplemental Figure S6(B). Among the 78 studies that report mortality, the prevalence is 2.0% (95% CI 1.6%; 2.5%), n = 14,262, I2 = 38.3%, Supplementary Figure S7(B).
Assessment of myocarditis
Among the 94 studies available, only 80 could be used to extract information regarding the prevalence of myocarditis. Either some authors did not respond to our requests to provide their number of myocarditis cases or there was incomplete data to determine the prevalence. For 45 studies (Denoted as Strict Criteria in Supplementary Table 3), we categorised a posteriori the clinical criteria to determine the number of myocarditis. Twenty-four studies (Denoted as Predetermined Criteria in Supplementary Table 3) already ascertained cases of myocarditis in their respective populations based on criteria that included left ventricular systolic dysfunction on echocardiogram plus elevated troponin and/or brain natriuretic peptide. Four studies Reference Ramcharan, Nolan and Lai22,Reference Grimaud, Starck and Levy38,Reference Haslak, Barut and Durak57,Reference Toubiana, Poirault and Corsia97 within this subcategory further validated the diagnosis of myocarditis by requiring electrocardiographic changes such as ST-segment elevation/depression. Eight studies (Denoted as CMR in Supplementary Table 3) diagnosed myocarditis via cardiac resonance imaging using the Lake Louise criteria. Three studies Reference Erol and Sari10,Reference Vukomanovic, Krasic and Prijic80,Reference DeBiasi, Harahsheh and Srinivasalu92 had zero cases of myocarditis. The specific definitions of left ventricular systolic dysfunction and parameters for normal troponin, brain natriuretic peptide, and pro-brain natriuretic peptide are mentioned in Supplementary Table S3.
Discussion
To address the heterogeneity of various small case series and cohorts, this systematic review aimed to evaluate the prevalence of common cardiac manifestations in afflicted critically ill children with multisystem inflammatory syndrome in children. To our knowledge, this is the first meta-analysis looking at the prevalence from such a robust sample (n = 14,932). Overall, the quality of evidence was good with 64% of studies having a low risk of bias and 24% a moderate risk of bias.
Severe multisystem inflammatory syndrome in children presents with shock requiring vasopressors to sustain haemodynamics. Early systematic reviews report a prevalence range from 40 to 52% Reference Ahmed, Advani and Moreira99,Reference Kaushik, Gupta, Sood, Sharma and Verma100 while single international studies show 70 to 80% utilisation. Reference de Caro-Patón, de Azagra-Garde, García-Salido, Cabrero-Hernández, Tamariz and Nieto-Moro11,Reference Belhadjer, Méot and Bajolle33,Reference Acevedo, Piñeres-Olave and Niño-Serna82 This may be plausible as some middle and lower-income countries have higher comorbid patients, reduced disease recognition, and slower access to healthcare. In our analysis, vasopressors continue to be critical in shock management as the prevalence was 48.2% (95% CI 45.1%, 51.3%). In shock, cardiac dysfunction is frequently evaluated with an echocardiogram to assess left ventricular ejection fraction. Caution is necessary when interpreting this parameter because it is a volume-based measure that is preload dependent and subject to vasoactive use. Reference Basu, Kim and Sharron48,Reference Hejazi, Loke and Harahsheh101 Myocardial tissue motion and deformation estimates with strain echocardiography are independent of these loading conditions, and indexes such as global longitudinal strain and early diastolic strain rate may be an option to grade ventricular dysfunction more accurately. This detects impaired function even when cardiac magnetic resonance proved myocarditis reveals a preserved left ventricular ejection fraction. Reference Kavurt, Bağrul and Gül2,Reference Kobayashi, Dionne and Ferraro5,Reference Basu, Kim and Sharron48,Reference Matsubara, Kauffman and Wang64,Reference Sanil, Misra and Safa72 However, in keeping with consistency of measurements more commonly reported, we evaluated cardiac dysfunction via left ventricular systolic dysfunction. We reported a prevalence of 37.2% (95% CI 34.1%, 40.3%) compared to a previously described range of 32–58%. Reference Alsaied, Tremoulet and Burns23,Reference Ahmed, Advani and Moreira99,Reference Kaushik, Gupta, Sood, Sharma and Verma100 This left ventricular systolic dysfunction requires outpatient follow-up with echocardiograms because it can persist even after 1 month from hospitalisation Reference Basar and Sonmez46,Reference Capone, Misra and Ganigara84,Reference Farooqi, Chan and Weller91 with some residual left ventricular functional dysfunction Reference Belhadjer, Méot and Bajolle33,Reference Basar and Sonmez46,Reference Sanil, Misra and Safa72,Reference Theocharis, Wong and Pushparajah76,Reference Capone, Misra and Ganigara84,Reference Bagri, Deepak and Meena88,Reference Farooqi, Chan and Weller91,Reference Tiwari, Balan and Rauf96 persisting 2–6 weeks after discharge.
Other non-invasive imaging such as cardiac magnetic resonance is useful for functional assessment and structural changes like in myocarditis. Reference Aeschlimann, Misra and Hussein83,Reference Caforio, Pankuweit and Arbustini102 Despite its sensitivity in detecting inflammation, its availability is limited Reference Minocha, Phoon, Verma and Singh17,Reference Sirico, Basso and Reffo28,Reference Bermejo, Bautista-Rodriguez and Fraisse50,Reference Felsenstein, Willis and Lythgoe56,Reference Theocharis, Wong and Pushparajah76,Reference Valverde, Singh and Sanchez-de-Toledo79,Reference Aeschlimann, Misra and Hussein83,Reference Capone, Misra and Ganigara84 as evidenced by the few studies we identified. Twenty-four incorporated the criteria Reference Caforio, Pankuweit and Arbustini102 where ≥1 clinical presentation and ≥1 diagnostic criteria were sufficient for clinical diagnosis (Predetermined Criteria in Supplemental Table 3). To improve the accuracy in our analysis, we elected to make criteria stricter by needing ≥2 diagnostic criteria: cardiac biomarkers (abnormal troponin and/or pro-brain natriuretic peptide) + left ventricular systolic dysfunction (ejection fraction <55%) in addition to the clinical presentation Reference Caforio, Pankuweit and Arbustini102 (Strict Criteria in Supplemental Table 3). Our analysis therefore elicited a prevalence of 34.1% (95% CI 30.5%, 37.8%). Our results lie at the higher end of previous estimates, which reported a prevalence from 23 to 33%. Reference Kaushik, Gupta, Sood, Sharma and Verma100,Reference Hejazi, Loke and Harahsheh101 Even though children overall improve shortly after the diagnosis of multisystem inflammatory syndrome in children is made, long-term complications such as fibrosis, dilated cardiomyopathy, and arrhythmias may present thus warranting close monitoring. Reference Erol and Sari10 Ventricular dysrhythmias in dilated cardiomyopathy are lethal complications of multisystem inflammatory syndrome in children-induced myocarditis in the latter stages but dysrhythmias overall can present early on with 7–60% of patients Reference Alsaied, Tremoulet and Burns23 having irritable foci. Despite the heterogeneity of studies, we were unable to perform further analyses looking at the prevalence of certain rhythms as the reporting of electrocardiographic information was inconsistent and infrequent. Those studies that were, are listed in Supplementary Table S3. From the studies that did cite this data, the calculated prevalence of electrocardiographic abnormalities was 23.1% (95% CI 18.8%, 27.6%). Despite the severity and potential for worsening progression, these dysrhythmias (including first-degree atrio-ventricular block) typically resolve within the first 2 weeks Reference Clark, Sanchez-de-Toledo and Bautista-Rodriguez1,Reference Ramcharan, Nolan and Lai22,Reference Hejazi, Loke and Harahsheh101 before the 2-week follow-up. Reference Dionne, Mah and Son9 The present literature describes only one report of three patients with persistent asymptomatic bradycardia lasting through the 2-month follow-up. Reference Erol and Sari10
Coronary abnormalities which can take months to resolve are the opposite of the swifter trajectory for healing seen in dysrhythmias. Resolution typically occurs in 79% of cases by 1 month Reference Felsenstein, Willis and Lythgoe56 and in 100% of cases by 3 months. Reference Rakha, Sobh and Hager71,Reference Patnaik, Jain and Ahmed103 In our patient cohort, the prevalence of coronary abnormalities was 18.0% (95% CI 16.0%; 20.0%) in comparison to the described 6–24%. Reference Suresh Kumar, Awasthi and Thakur8,Reference Sözeri, Çağlayan and Atasayan21,Reference Alsaied, Tremoulet and Burns23,Reference Ahmed, Advani and Moreira99–Reference Hejazi, Loke and Harahsheh101 Some had residual aneurysms Reference Cheung, Zachariah and Gorelik53 and dilation after 2 weeks, Reference Capone, Misra and Ganigara84 4–6 weeks Reference Rakha, Sobh and Hager71,Reference Bagri, Deepak and Meena88,Reference Tiwari, Balan and Rauf96 , 8 weeks Reference Capone, Misra and Ganigara84,Reference Fabi, Filice and Biagi90 , and by 3 months Reference Tiwari, Balan and Rauf96 post-discharge. We were unable to complete an analysis of the total cases of coronary dilations versus coronary aneurysms since some studies did not define them aside from the term “coronary abnormalities” or simply did not report them as findings. Of those in Supplementary Table S3, we tallied 717 total cases of coronary abnormalities with 300 coronary dilations (41.8%) and 367 coronary aneurysms (51.2%). Other variations of abnormalities included those describing arteries as hyperechoic, prominent, or lacking tapering. Regardless of the presentation, the evolution of the abnormality is imperative to monitor over the ensuing months as one patient had a stable medium coronary aneurysm (Z-score 9.8) 6 months out from discharge; these can become giant raising the risk of a myocardial infarction. Reference Bautista-Rodriguez, Sanchez-de-Toledo and Clark47,Reference Hejazi, Loke and Harahsheh101
Even though most patients recover rather uneventfully once medical therapies are initiated, some are affected with ventricular dysrhythmias, refractory shock, and/or acute heart failure. Reference Capone, Subramony and Sweberg7,Reference Alsaied, Tremoulet and Burns23 These severe cases go can extend beyond vasopressor and mechanical ventilation management to necessitate extracorporeal membrane oxygenation support. Early in the pandemic, Belhadjer et al Reference Belhadjer, Méot and Bajolle33 published that 28% of patients at their centres required the intervention. Subsequently, Ahmed et al Reference Ahmed, Advani and Moreira99 published one of the first systematic reviews on multisystem inflammatory syndrome in children to mention that prevalence was closer to 4.4%. Our meta-analysis revealed a pool prevalence of 2.2% (95% CI 1.7%, 2.8%) [Supplementary Figure 6Sa]. This value is half as frequent likely because as more waves of COVID-19 have passed, there has been increased awareness of multisystem inflammatory syndrome in children, improvements of its management, and a decline in the severe outcomes of multisystem inflammatory syndrome in children. Reference Miller, Zambrano and Yousaf27 As a result, reviews have observed a mortality of ∼1–2%. Reference Alsaied, Tremoulet and Burns23,Reference Kaushik, Gupta, Sood, Sharma and Verma100,Reference Hejazi, Loke and Harahsheh101 which is in concord with our prevalence of 2.2% (95% CI 1.7%, 2.7%) [Supplementary Figure 7Sa].
Strengths and Limitations
We evaluated 94 studies using a uniform definition of multisystem inflammatory syndrome in children thus providing a robust sample to calculate the precise prevalence of different cardiac manifestations. Additionally, we had a high proportion of articles with a low risk of bias and a high heterogeneity. Limitations include that most studies chosen involved retrospective data. And as for all meta-analyses, our findings were limited by the quality of evidence of the studies included. There was heterogeneity in how some outcomes were described and reported. For example, the definition of myocarditis was frequently based on clinical assessment and rarely on MRI. Due to differences in the definition of left ventricular systolic dysfunction and imaging strategies chosen, it is possible that not all patients with suspected myocarditis were systematically screened thus underestimating the true prevalence. Also, the use of brain natriuretic peptide or troponin in assessing myocardial involvement can be misleading as both can increase from sepsis. Additionally, each paper referenced a different range of normal depending on the institution’s lab. The extent of our findings from electrocardiography is also hindered by the lack of consistent reporting from multiple groups.
Conclusions
In a meta-analysis and systematic review of multisystem inflammatory syndrome in children literature, we assessed the most common cardiac manifestations of these critically ill children. We determined a prevalence of cardiac complications from a population of 14,932 patients. Among those admitted to a critical care unit for multisystem inflammatory syndrome in children, half required vasoactive support, one-third had left ventricular systolic dysfunction, one-third had myocarditis, one quarter had electrocardiographic abnormalities, one-sixth had coronary abnormalities, and 2% required extracorporeal support with an overall mortality rate of 2%. Further research is still critical in determining the appropriate long-term follow-up and consequences, especially in those with coronary abnormalities and myocarditis which might persist for months. Appropriate cardiac re-examinations with specific imaging modalities may ensure the safety of children in otherwise apprehensive families as these cardiac sequelae resolve.
Supplementary material
To view supplementary material for this article, please visit https://doi.org/10.1017/S104795112300015X
Acknowledgements
We would like to thank Emily Ansusinha, MA (Children’s National Hospital, Washington DC) and Dr Ryan Dunne (Stony Brook Medicine, NY) for data gathering. We thank Nancy Aldrich, MLIS (Advent Health Orlando) for her assistance in conducting the initial literature search. We would like to thank Dr Fatma Levent (Advent Health Orlando) for the original idea prompting this manuscript to be undertaken. We are grateful to Dr Christopher Snyder (Children’s Hospital of Richmond) for his expertise and review of the manuscript. We would like to acknowledge all the authors who provided additional information that allowed us to perform this meta-analysis. In particular, we would like to thank Susanna Felsenstein (Alder Hey Children’s NHS Foundation Trust Hospital, Liverpool), Ashraf Harahsheh (Children’s National Hospital, Washington DC), Ahmet Vedat Kavurt (Ankara City Hospital, Ankara, Turkey), Pui Lee (Boston Children’s Hospital, Massachusetts), Fernanda Lima-Setta (Instituto D’Or de Pesquisa e Ensino (IDOR), Departamento de Pediatria, Rio de Janeiro, Brazil), Daisuke Matsubara (The Children’s Hospital of Philadelphia, Pennsylvania), Carmen Nino-Taravilla (Clinica INDISA, Chile), and Orkun Tolunay (University of Health Sciences Adana City Training and Research Hospital, Turkey) for the exceptional amount of time spent to provide the requested data.
Financial support
This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.
Conflicts of interest
None.